Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma
Marlon C. Rebelatto(AstraZeneca (Japan)), Jill Walker(AstraZeneca (United Kingdom))
Cited by 179
Related Papers
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC
|Journal of Thoracic Oncology|2022|72